Login / Signup

NK cell-triggered CCL5/IFNγ-CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer.

Sara Santana-HernándezJesús Suarez-OlmosSonia ServitjaPau Berenguer-MolinsMarcel Costa-GarciaLaura ComermaAnna ReaJulia Perera-BelSilvia MenendezOriol ArpíBegoña BermejoMaría Teresa MartínezJuan Miguel CejalvoIñaki Comino-MéndezJavier PascualEmilio AlbaMiguel López-BotetFederico RojoAna RoviraJoan AlbanellAura Muntasell
Published in: Journal of experimental & clinical cancer research : CR (2024)
This study identifies specialized NK cell subsets as the source of IFN-ɣ influencing the clinical efficacy of anti-HER2 antibodies. It also reveals the potential of serum CCL5/CXCL9 as biomarkers for identifying patients with NK cell-rich tumors and favorable responses to anti-HER2 antibody-based neoadjuvant treatment.
Keyphrases
  • nk cells
  • rectal cancer
  • lymph node
  • immune response
  • dendritic cells
  • liver injury
  • palliative care
  • liver fibrosis
  • squamous cell carcinoma
  • gene expression
  • genome wide
  • drug induced
  • young adults
  • childhood cancer